ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
98,250.02
-0.06%
S&P 500
5,942.47
1.26%
Dow Jones
42,732.13
0.80%
US Dollar vs Yen
157.751
0.15%
Brent Oil
76.495
-0.01%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Cytokinetics Inc (CYTK)

  7. Cytokinetics Inc (CYTK) ニュース

CYTK

Cytokinetics (CYTK)

Cytokinetics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CYTK
日付受信時刻ニュースソース見出しコード企業名
2025/01/0406 : 00GlobeNewswire Inc.Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:CYTKCytokinetics Inc
2024/12/2321 : 30GlobeNewswire Inc.Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyNASDAQ:CYTKCytokinetics Inc
2024/12/2014 : 00GlobeNewswire Inc.Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater ChinaNASDAQ:CYTKCytokinetics Inc
2024/12/1709 : 23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
2024/12/1706 : 38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTKCytokinetics Inc
2024/12/1706 : 13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
2024/12/1306 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
2024/12/1107 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
2024/12/1106 : 06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
2024/12/0606 : 32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
2024/12/0606 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
2024/12/0606 : 28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
2024/12/0606 : 22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
2024/12/0606 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
2024/12/0406 : 00GlobeNewswire Inc.Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CYTKCytokinetics Inc
2024/12/0321 : 30GlobeNewswire Inc.Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection FractionNASDAQ:CYTKCytokinetics Inc
2024/12/0308 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
2024/12/0306 : 01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
2024/12/0306 : 00GlobeNewswire Inc.Cytokinetics to Participate in December Investor ConferencesNASDAQ:CYTKCytokinetics Inc
2024/12/0221 : 30GlobeNewswire Inc.Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyNASDAQ:CYTKCytokinetics Inc
2024/11/2709 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
2024/11/2707 : 38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
2024/11/2706 : 09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
2024/11/2606 : 10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
2024/11/2006 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
2024/11/1920 : 02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTKCytokinetics Inc
2024/11/1916 : 30GlobeNewswire Inc.Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in JapanNASDAQ:CYTKCytokinetics Inc
2024/11/1906 : 31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
2024/11/1623 : 00GlobeNewswire Inc.Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024NASDAQ:CYTKCytokinetics Inc
2024/11/1623 : 00GlobeNewswire Inc.Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024NASDAQ:CYTKCytokinetics Inc
 Showing the most relevant articles for your search:NASDAQ:CYTK

最近閲覧した銘柄

COIN
AVAXUSD
Avalanche
USOTC
ADDYY
Adidas (QX)
NYSE
KO
Coca Cola
NYSE
MRK
Merck
FX
USDJPY
US Dollar vs Yen
NASDAQ
TSLA
Tesla
NYSE
VZ
Verizon Communications
AMEX
SPY
SPDR S&P 500
COIN
ADAUSD
Cardano
USOTC
RHHBY
Roche (QX)
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
MSFT
Microsoft
NYSE
JPM
JP Morgan Chase
NASDAQ
NVDA
NVIDIA
FX
USDGBP
US Dollar vs Sterling
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有